V alvular thrombosis, systemic emboli, and hemorrhage from anticoagulation are major complications of heart valve replacement with mechanical prostheses. The surgical valve replacement and thrombolytic therapy were discussed with each patient. All patients were required to sign an informed consent form before thrombolytic therapy was begun. The first two patients were treated with streptokinase (250,000 units bolus i.v. injection over 30 minutes followed by a maintenance infusion of 100,000 units/hr for 72 hours). However, the second patient had received streptokinase previously during a myocardial infarction and had a high antibody titer. This patient and subsequent patients were therefore treated with urokinase. Urokinase was given according to the same protocol recommended for treatment of pulmonary embolism: a bolus injection of 4,400 units/kg given over 10-15 minutes followed by a maintenance dose of 4,400 units . kg.* hr-'. Two patients received only heparin as therapy. One of these patients presented with a cerebrovascular accident of embolic origin, and fibrinolytic agents were thought to be contraindicated.
Thrombolytic therapy was terminated if normalization of valve function was documented on cinefluoroscopy, if hemorrhagic complications prevented continuation of therapy, or after 24 hours if no improvement had occurred. After discontinuation of the thrombolytic agent, patients were heparinized when the partial thromboplastin time dropped to less than two times control, generally without a heparin bolus, and discharged on warfarin titrated to a prothrombin time of 1.5-2.0 times control and dipyridamole.
Follow-up
Follow-up was obtained annually by mailed questionnaire or by direct patient contact by a trained research nurse and was available in all patients treated medically for PVT.
Statistical Analysis
Data are expressed as the mean±SD. The statistical significance of the differences was analyzed by use of Student's t test.
Results

Clinical Presentation
The clinical characteristics of the patients are presented in Table 1 (Figure 3 ). All patients were released from the hospital and were followed by their cardiologists. None of these patients required subsequent surgery. At 3-month follow-up, all were alive and well.
Patients With Recurrent Events
Recurrent events are outlined in 
Embolization
Only one patient had a transient ischemic attack related to embolization, which resolved completely within 2 hours. This experience is similar to that of Kurzrok et al,21 who found that all manifestation of embolization disappeared within 2 days. Thus, it seems that after thrombolytic therapy, the majority of patients with a thrombosed prosthesis in the left side of the heart will not develop permanent neurological sequelae caused by systemic embolization. These data are also in accordance with observations of patients receiving urokinase for left ventricular thrombus after myocardial infarction.27
Choice of Thrombolytic Agents
To decrease the risk of embolization, we believe a less intense but more prolonged thrombolytic state is desirable than is used for treatment of acute myocardial infarction. This is the primary reason that we have selected the urokinase protocol discussed in the "Methods" section. Urokinase has been used successfully in this manner for dissolution of peripheral arterial as well as pulmonary artery thrombi and also has the advantage of a lack of hemodynamic and allergenic effects. In two of our patients, heparin alone resulted in significant improvement, and its value as sole agent of treatment should be evaluated in further studies.
Role of Cinefluoroscopy and Doppler Echocardiography
In our experience, cinefluoroscopy is a simple and accurate method both for diagnosis of St. Jude PVT and to follow the response to thrombolytic treatment. Dopp 
